Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Kidney transplantation
8 evidence topics · 8 sources
Preemptive transplantation: KDIGO 2024 CKD guideline
Transplant access for Black people with kidney failure in the United States
Allograft survival of kidneys from deceased donors with two APOL1 risk variants
“Combined analysis of 1153 DDKTs from AA donors revealed donor APOL1 high-risk genotype (HR 2.05; p=3×10−4), older donor age (HR 1.18; p=0.05), and younger recipient age (HR 0.70; p=0.001) adversely impacted allograft survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A competing risk analysis revealed that APOL1 impacted renal allograft survival, but not recipient survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Allograft survival by recipient APOL1 genotype
“Recipients carrying two APOL1 RA demonstrated lower graft survival compared to recipients with only one or none of APOL1 RA at 1-year posttransplant independently of other donor and recipient characteristics (Adjusted HR 3.2 [95% CI 1.0–10.4, p-value 0.05]). There was no significant difference in overall survival or graft survival after 3 years posttransplantation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Kidney function after living donation by APOL1 genotype: APOLLO
“Sixty-eight Black donors (15.3%) had APOL1 high-risk genotypes (G1/G1, G2/G2, or G1/G2).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Black kidney donors with APOL1 high-risk genotypes had a higher risk of developing an eGFR of less than 45 mL/min/1.73 m2 than Black kidney donors without APOL1 high-risk genotypes (relative risk, 2.31; 95% CI, 1.16-4.61; P = .02) (after adjustment for predonation eGFR: relative risk, 1.91; 95% CI, 0.90-4.03; P = .09).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
FSGS recurrence and donor APOL1 testing: KDIGO 2021 glomerular diseases guideline
Implications for kidney transplantation: KDIGO 2025 APOL1 conference report
“In the United States, living donors with APOL1 high-risk genotypes more often develop advanced CKD post donation” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“but recipients with high-risk APOL1 genotypes may also have reduced graft survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Agents must be shown to be safe in the transplant setting, including lack of interaction with immunosuppressive agents.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Monitoring for recurrent HIVAN after transplantation
“Given the strong association between the APOL1 risk variants and HIVAN, HIV-positive recipients of African descent and those who receive an allograft from a donor of African descent should be monitored for recurrent HIVAN.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote